A-1210477 is a novel, potent and specific MCL-1 (Myeloid cell leukemia-1) inhibitor with Ki and IC50 of 0.45 nM and 26.2 nM, respectively.

Pyridoclax, formerly known as MR29072, is a potent and selective Mcl-1 inhibitor.

10-Deacetyl-7-xylosyl paclitaxel, a Paclitaxel analog, is a metabolite of Paclitaxel (TAXOL) which is a microtubule stabilizing agent/tubulin inhibitor and chemotherapeutic drug approved to treat various cancers.

BAI1 is a novel, potent and direct allosteric inhibitor of BAX with a dissociation constant (Kd) of 15.0 ± 4 μM.

AT-101 [(R)-(-)-Gossypol acetic acid, the levorotatory isomer of a natural product Gossypol], is a novel, oral and potent inhibitor of Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; it shows no inhibition against BIR3 and BID.

Marinopyrrole A (also known as Maritoclax) is a natural product and a selective antagonist of Mcl-1 with anticancer activity.

BT2 is a novel and potent inhibitor of branched-chain alpha-ketoacid dehydrogenase kinase.

Jaceosidin is a novel and potent methylated trihydroxyflavone.

Navitoclax (formerly ABT-263) is a novel, highly potent, orally bioavailable small-molecule inhibitor of the BCL (B-cell leukemia) protein family such as Bcl-xL, Bcl-2 and Bcl-w with Ki of ~ 0.5 nM, ~1 nM and ~1 nM in cell-free assays.

CID5721353 (also known as BCL6 Inhibitor and 79-6) is a novel and potent inhibitor of BCL6 (B-Cell Lymphoma 6) with an IC50 value of 212 μM (equivalent to a Ki of 147 μM).